GeNeuro responsible for development of GNbAC1 till completion of Phase IIb in Multiple Sclerosis, receiving $47M from Servier, after which Servier can exercise licensing option in all markets excluding the USA and Japan.
- GeNeuro retains independence & full control of the U.S. & Japan and for applications of its technology in other diseases.
- After exercising option, Servier will cover Phase III global development costs and pay GeNeuro up to US$408M in future development and sales milestones, as well as royalties on future sales.
- Servier will also have the option to take an equity stake in GeNeuro as a minority shareholder in 2015.
December 2, 2014, Geneva, Switzerland, and Suresnes, France – GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has entered into a strategic partnership with Servier, the leading independent French pharmaceutical company, to develop and market GNbAC1 in Multiple Sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.
Further information can be found at: